Liuwei Dihuang Pill (六味地黄丸) Treats Postmenopausal Osteoporosis with Shen (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression

Ji-rong Ge; Li-hua Xie; Juan Chen; Sheng-qiang Li; Hui-juan Xu; Yu-lian Lai; Long-long Qiu; Chen-bo Ni

doi:10.1007/s11655-016-2744-2

Your Location：

Home >

Browse articles >

Liuwei Dihuang Pill (六味地黄丸) Treats Postmenopausal Osteoporosis with Shen (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression

OriginalPaper | Updated：2021-08-27

- Liuwei Dihuang Pill (六味地黄丸) Treats Postmenopausal Osteoporosis with Shen (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression
- Liuwei Dihuang Pill (六味地黄丸) Treats Postmenopausal Osteoporosis with Shen (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression
- 中国结合医学杂志（英文版） 2018年24卷第6期页码：415-422
- Affiliations：
  
  Key Research Laboratory of Osteoporosis Syndrome Genomics, Fujian Academy of Traditional Chinese Medicine,Fuzhou,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-016-2744-2
  中图分类号：
- 纸质出版日期：2018，
  
  网络出版日期：2016-12-27，
Scan for full text
Ge, Jr., Xie, Lh., Chen, J. et al. Liuwei Dihuang Pill (六味地黄丸) Treats Postmenopausal Osteoporosis with Shen (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression., Chin. J. Integr. Med. 24, 415–422 (2018). https://doi.org/10.1007/s11655-016-2744-2

Ji-rong Ge, Li-hua Xie, Juan Chen, et al. Liuwei Dihuang Pill (六味地黄丸) Treats Postmenopausal Osteoporosis with Shen (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression[J]. Chinese Journal of Integrative Medicine, 2018,24(6):415-422.
Ge, Jr., Xie, Lh., Chen, J. et al. Liuwei Dihuang Pill (六味地黄丸) Treats Postmenopausal Osteoporosis with Shen (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression., Chin. J. Integr. Med. 24, 415–422 (2018). https://doi.org/10.1007/s11655-016-2744-2 DOI：

Ji-rong Ge, Li-hua Xie, Juan Chen, et al. Liuwei Dihuang Pill (六味地黄丸) Treats Postmenopausal Osteoporosis with Shen (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression[J]. Chinese Journal of Integrative Medicine, 2018,24(6):415-422. DOI： 10.1007/s11655-016-2744-2.

摘要

To investigate the mechanism of Liuwei Dihuang Pill (六味地黄丸

LDP) in treating postmenopausal osteoporosis (PMOP) with Shen (Kidney) yin deficiency. In this study

205 cases of PMOP were divided into the PMOP Shen-yin deficiency group (Group A)

PMOP Shen-yang deficiency group (Group B)

PMOP without Shen deficiency group (Group C)

and control group (Group N). Real-time polymerase chain reaction (RT-PCR) and Western blot techniques were used to observe the effects of LDP treatment on the cardiotrophin-like cytokine factor 1 (CLCF1)

ankyrin repeat and SOCS box containing 1 (ASB1)

and prokineticin 2 (PROK2) genes and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. The mRNA (P<0.05) and protein (P<0.01) expression levels of the CLCF1 gene in Group A were significantly lower than the corresponding levels in Group N. After LDP treatment for 3 months

the mRNA expression levels of the CLCF1 gene were obviously up-regulated (P<0.01). After 6-month treatment

the expression levels of CLCF1 mRNA and protein were significantly up-regulated (both P<0.01)

and the average bone density of the top femur had significantly increased (P<0.05). In vitro

CLCF1 overexpression resulted in a significant increase in the total protein and phosphorylated protein levels of JAK2 and STAT3. The CLCF1 gene is an important gene associated with PMOP Shen-yin deficiency and the therapeutic effects of LDP may be mediated by up-regulation of CLCF1 gene expression and activation of the JAK/STAT signaling pathway.

Abstract

To investigate the mechanism of Liuwei Dihuang Pill (六味地黄丸

LDP) in treating postmenopausal osteoporosis (PMOP) with Shen (Kidney) yin deficiency. In this study

205 cases of PMOP were divided into the PMOP Shen-yin deficiency group (Group A)

PMOP Shen-yang deficiency group (Group B)

PMOP without Shen deficiency group (Group C)

ankyrin repeat and SOCS box containing 1 (ASB1)

the mRNA expression levels of the CLCF1 gene were obviously up-regulated (P<0.01). After 6-month treatment

the expression levels of CLCF1 mRNA and protein were significantly up-regulated (both P<0.01)

and the average bone density of the top femur had significantly increased (P<0.05). In vitro

关键词

postmenopausal osteoporosisChinese MedicineShen (Kidney) yin deficiencycardiotrophinlike cytokine factor 1 geneLiuwei Dihuang PillJanus kinase/signal transducer and activator of transcription signaling pathway

Keywords

references

Scott LJ. Denosumab: a review of its use in postmenopausal women with osteoporosis. Drugs Aging 2014;31:555–576.

Li DT, Li FY, Wang J, Liu JH, Yan N, Cheng YM, et al. A study of diagnostic criteria for traditional Chinese medicine syndromes in osteoporosis. J Chin Integr Med (Chin) 2011;9:1326–1332.

Xia BJ, Tong PJ, Sun Y, Zhou LY, Jin HT. Methods and evaluations on the sterioid-induced osteoporosis mice model with the type of Kidney-yin deficiency. China J Orthop Traumatol (Chin) 2014;27:673–679.

Xie LH, Zhao YP, Chen K, et al. Bioinformatics analysis of genes expression profiles of postmenopausal osteoporosis with Kidney yin deficiency. J Clin Rehab Tissue Engin Res (Chin) 2011;15:2833–2837.

Tarca AL, Bhatti G, Romero R. A comparison of gene set analysis methods in terms of sensitivity, prioritization and specificity. PLoS One 2013;8:e79217.

Chamorro CI, Zeiai S, Engberg GR, Brodin D, Nordenskjöld A, Fossum M. A study on proliferation and gene expression in normal human urothelial cells in culture. Tissue Eng Patr A 2015;21:510–517.

Xie YM, Yuwen Y, Dong FH, Sun SC, Wang HM, Liu QS, et al. Clinical practice guideline of traditional medicine for primary osteoporosis. Chin J Integr Med 2011;17:52–63.

Jiang M, Lu C, Zhang C, Yang J, Tan Y, Lu A, et al. Syndrome differentiation in modern research of traditional Chinese medicine. J Ethnopharmacol 2012;140:634–642.

Peacock M, Turner CH, Econs MJ, Foroud T. Genetics of osteoporosis. Endoc Rev 2002;23:303–326.

Sugiya N, Nakashima A, Takasugi N, Kawai A, Kiribayashi K, Tanaka J, et al, Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life. Osteoporos Int 2011;22:1573–1579.

Nakashima T, Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 2009;29:555–567.

Liu ZH, ed. Osteoporosis research and prevention. Beijing: Chemical Industry Press; 1994:226–261.

Xia B, Xu B, Sun Y, Xiao L, Pan J, Jin H, et al. The effects of Liuwei Dihuang on canonical Wnt/β-catenin signaling pathway in osteoporosis. J Ethnopharmacol 2014;153:133–141.

Zhou P, Zhou Q. Observation of the Liuwei Dihuang Pill treatment of 30 cases of osteoporosis in older men. Shanxi J Tradit Chin Med (Chin) 2014;35:1191–1192.

Zhang HB, Li CY. Effect of Liuwei Dihuang Pill on bone mineral density of the primary osteoporosis (Shen yin deficiency). Chin J Tradit Med Traumatol Orthop (Chin) 2011;19:18–20.

Fu B, Lun X, Gong Y. Effects of the combined therapy of acupuncture with herbal drugs on male immune infertility—a clinical report of 50 cases. J Tradit Chin Med 2005;25:186–189.

Erices A, Conget P, Rojas C, Minguell JJ. GP130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymas stem cells. Exp Cell Res 2002;280:24–32.

Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci 2012;122:143–159.

Fang J, Zhang YX, Ru XB, Wei XL. Effect of liuwei dihuang decoction, on the cytokine expression in splenocytes in AA rats. China J Chin Mater Med (Chin) 2001;26:128–131.

Gao D, Zheng LP, Lin JM, Lin W, Chen XZ, Song J, et al. Experimental study on effect of Liuwei Dihuang Pill on HSC from mouse marrow. J Chin Med Mater (Chin) 2008;31:251–254.

Elsaeidi F, Bemben MA, Zhao XF, Goldman D. Jak/Stat signaling stimulates zebrafish optic nerve regeneration and overcomes the inhibitory actions of Socs3 and Sfpq. J Neurosci 2014;34:2632–2644.

Senaldi G, Varnum BC, Sarmiento U, Starnes C, Lile J, Scully S, et al. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc Natl Acad Sci U S A 1999;96:11458–11463.

Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, et al. Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br J Haematol 2003;123:869–878.

Elson GC, Lelièvre E, Guillet C, Chevalier S, Plun-Favreau H, Froger J, et al. CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat Neurosci 2000;3:867–872.

Moortgat S, Benoit V, Deprez M, Charon A, Maystadt I. A new Turkish infant with clinical features of CS/CISS1 syndrome and homozygous CRLF1 mutation. Eur J Med Genet 2014;57:212–215.

Hahn AF, Waaler PE, Kvistad PH, Bamforth JS, Miles JH, McLeod JG, et al. Cold-induced sweating syndrome CISS1 and CISS2: manifestations from infancy to adulthood. Four new cases. J Neurol Sci 2010;293:68–75.

Aljabari S, Howard E, Bell T, Vasylyeva TL. Cold induced sweating syndrome with urinary system anomaly association. Case Rep Pediatr 2013;2013:173890.

Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res 2013;76:1–8.

Joung YH, Lim EJ, Darvin P, Chung SC, Jang JW, Do Park K, et al. MSM enhances GH signaling via the Jak2/STAT5b pathway in osteoblast-like cells and osteoblast differentiation through the activation of STAT5b in MSCs. PLoS One 2012;7:e47477.

Huang E, Zhu G, Jiang W, Yang K, Gao Y, Luo Q, et al. Growth hormone synergizes with BMP9 in osteogenic differentiation by activating the JAK/STAT/IGF1 pathway in murine multilineage cells. J Bone Mineral Res 2012;27:1566–1575.

Li CH, Zhao JX, Sun L, Yao ZQ, Deng XL, Liu R, et al. AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis. Biochem Biophys Res Commun 2013;435:533–539.

Bellido T, Borba VZ, Roberson P, Manolagas SC. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 1997;138:3666–3676.

Nishimura R, Moriyama K, Yasukawa K, Mundy GR, Yoneda T. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J Bone Miner Res 1998;13:777–785.

Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potentialofanti-IL-6 therapies. Cancer Manag Res 2011;3:177–189.

Itoh S, Udagawa N, Takahashi N, Yoshitake F, Narita H, Ebisu S, et al. A critical role for interleukin-6 familymediated Stat3 activation in osteoblast differentiation and bone formation. Bone 2006;39:505–512.

Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1–20.

Abraham AK, Ramanathan M, Weinstock-Guttman B, Mager DE. Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol 2009;77:1757–1762.

Sun GJ, Guo T, Chen Y, Xu B, Guo JH, Zhao JN. Significant pathways detection in osteoporosis based on the bibliometric network. Eur Rev Med Pharmacol Sci 2013;17:1–7.

Platanias CL, Fish EN. Signaling pathways activated by interferons. Exp Hematol 1999;27:1583–1592.

González-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012;12:125–135.

Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011;124:776–778.

Kim S, Takayanagi H. The regulation of osteoclastogenesis by IFN. Nihon Rinsho 2005;63:1553–1561.

de Bruin AM, Voermans C, Nolte MA. Impact of interferon-γ on hematopoiesis. Blood 2014;124:2479–2486.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Effect of Ermiao Recipe (二妙方) with medicinal guide Angelicae Pubescentis Radix on promoting the homing of bone marrow stem cells to treat cartilage damage in osteoarthritis rats

Effects of Jianpi Jiedu Recipe (健脾解毒方) on reversion of P-glycoprotein-mediated multidrug resistance through COX-2 pathway in colorectal cancer